新辅助化疗和辅助化疗在胰腺癌中的作用

IF 0.6 Q4 ONCOLOGY Indian Journal of Surgical Oncology Pub Date : 2024-05-01 Epub Date: 2024-04-26 DOI:10.1007/s13193-024-01938-6

Govind Babu K, Venkata Pradeep Babu Koyyala

{"title":"新辅助化疗和辅助化疗在胰腺癌中的作用","authors":"Govind Babu K, Venkata Pradeep Babu Koyyala","doi":"10.1007/s13193-024-01938-6","DOIUrl":null,"url":null,"abstract":"Pancreatic cancer is an aggressive malignancy. Recurrences are very high despite high-quality surgery necessitating adjuvant therapy. The evolution of adjuvant therapy took several decades and gradually evolved from single-agent chemotherapy to multi-agent chemotherapy. The two important agents that are active in pancreatic cancer are 5-fluorouracil and gemcitabine, and with several combinations showing better results in the subsequent trials, the most recent trial PRODIGE 24 shows a median survival of 54.4 months. The role of neoadjuvant therapy is still evolving in resectable cancers. The role of adjuvant radiotherapy is not well defined due to controversial results from historical trials.","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"15 Suppl 2","pages":"315-321"},"PeriodicalIF":0.6000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11133239/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Role of Neoadjuvant and Adjuvant Chemotherapy in Pancreatic Cancer.\",\"authors\":\"Govind Babu K, Venkata Pradeep Babu Koyyala\",\"doi\":\"10.1007/s13193-024-01938-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pancreatic cancer is an aggressive malignancy. Recurrences are very high despite high-quality surgery necessitating adjuvant therapy. The evolution of adjuvant therapy took several decades and gradually evolved from single-agent chemotherapy to multi-agent chemotherapy. The two important agents that are active in pancreatic cancer are 5-fluorouracil and gemcitabine, and with several combinations showing better results in the subsequent trials, the most recent trial PRODIGE 24 shows a median survival of 54.4 months. The role of neoadjuvant therapy is still evolving in resectable cancers. The role of adjuvant radiotherapy is not well defined due to controversial results from historical trials.\",\"PeriodicalId\":46707,\"journal\":{\"name\":\"Indian Journal of Surgical Oncology\",\"volume\":\"15 Suppl 2\",\"pages\":\"315-321\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11133239/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Surgical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13193-024-01938-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/4/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Surgical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13193-024-01938-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/26 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

胰腺癌是一种侵袭性恶性肿瘤。尽管进行了高质量的手术，但复发率非常高，因此必须进行辅助治疗。辅助治疗的发展历经数十年，从单药化疗逐渐发展到多药化疗。5-氟尿嘧啶和吉西他滨是对胰腺癌有疗效的两种重要药物，在随后的试验中，几种药物的组合显示出更好的疗效，最近的试验 PRODIGE 24 显示中位生存期为 54.4 个月。新辅助治疗在可切除癌症中的作用仍在不断发展。由于历史试验的结果存在争议，辅助放疗的作用尚未明确。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The Role of Neoadjuvant and Adjuvant Chemotherapy in Pancreatic Cancer.

Pancreatic cancer is an aggressive malignancy. Recurrences are very high despite high-quality surgery necessitating adjuvant therapy. The evolution of adjuvant therapy took several decades and gradually evolved from single-agent chemotherapy to multi-agent chemotherapy. The two important agents that are active in pancreatic cancer are 5-fluorouracil and gemcitabine, and with several combinations showing better results in the subsequent trials, the most recent trial PRODIGE 24 shows a median survival of 54.4 months. The role of neoadjuvant therapy is still evolving in resectable cancers. The role of adjuvant radiotherapy is not well defined due to controversial results from historical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Surgical Oncology ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

190

期刊介绍： The Indian Journal of Surgical Oncology aims to encourage and promote clinical and research activities pertaining to Surgical Oncology. It also aims to bring in the concept of multidisciplinary team approach in management of various cancers. The Journal would publish original article, point of technique, review article, case report, letter to editor, profiles of eminent teachers, surgeons and instititions - a short (up to 500 words) of the Cancer Institutions, departments, and oncologist, who founded new departments.